MEDICAL DEVICE COATINGS WITH MICROCRYSTALLINE ACTIVE AGENTS
Embodiments herein relate to medical devices and coatings for the same. In an embodiment, a drug delivery coating can be included having a polymeric layer. The polymeric layer can include a hydrophilic outer surface. The drug delivery coating can also include an active agent layer disposed over the polymeric layer. The active agent layer can include a microcrystalline active agent and a cationic agent. Other embodiments are also included herein.
1 . A drug delivery coating comprising:
a polymeric layer, the polymeric layer comprising a hydrophilic outer surface;
an active agent layer, wherein the active agent layer is disposed over the polymeric layer, the active agent layer comprising
a microcrystalline active agent; and
a cationic agent.
2 . The drug delivery coating of claim 1 , wherein the microcrystalline active agent has an average particle size of less than 50 μm.
3 . The drug delivery coating of claim 1 , wherein the microcrystalline active agent has an average particle size of less than 20 μm.
4 . The drug delivery coating of claim 1 , wherein the microcrystalline active agent is at least 95 percent crystalline.
5 . The drug delivery coating of claim 1 , wherein the total amount of amorphous active agent in the active agent layer is less than 5% by weight.
6 . The drug delivery coating of claim 1 , the microcrystalline active agent comprising sirolimus.
7 . The drug delivery coating of claim 1 , the cationic agent comprising at least one selected from the group consisting of polyethyleneimine (PEI), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), and polyamidoamine dendrimers (PAMAM).
8 . The drug delivery coating of claim 1 ,
wherein the microcrystalline active agent is arranged leaving gaps between some adjacent crystals; and
wherein the cationic agent fills at least some of the gaps.
9 . The drug delivery coating of claim 8 , wherein at least some gaps remain unfilled.
10 . The drug delivery coating of claim 1 , wherein the cationic agent coats at least some crystals of the microcrystalline active agent.
11 . The drug delivery coating of claim 1 , the polymeric layer further comprising a hydrophilic polymer.
12 . The drug delivery coating of claim 11 , the hydrophilic polymer comprising at least one selected from the group consisting of a methacrylamide and a polyvinylpyrrolidone.
13 . The drug delivery coating of claim 11 , the hydrophilic polymer comprising a methacrylamide copolymer.
14 . The drug delivery coating of claim 11 , the hydrophilic polymer comprising a photoreactive methacrylamide copolymer.
15 . The drug delivery coating of claim 11 , the hydrophilic polymer comprising poly[N-(3-aminopropyl)methacrylamide-co-N-(3-(4-benzoylbenazmido)propyl)methacrylamide].
16 . The drug delivery coating of claim 1 , the polymeric layer further comprising a photoreactive crosslinking agent.
17 . The drug delivery coating of claim 16 , the photoreactive crosslinking agent comprising ethylenebis (4-benzoylbenzyldimethylammonium) dibromide.
18 . The drug delivery coating of claim 1 , the polymeric layer further comprising a methacrylamide.
19 . The drug delivery coating of claim 1 , the polymeric layer further comprising a polyvinylpyrrolidone.
20 . The drug delivery coating of claim 1 , the active agent layer further an additive, the additive comprising at least one selected from the group consisting of glycogen, dextran, and F68 poloxamer.